Dementias Caused by Persistent Pathogens and the Protective Role of HLA Against them

Lisa M. James1,2,3, Apostolos P. Georgopoulos1,2,3,4

1Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, USA
2Department of Neuroscience, University of Minnesota Medical School, Minneapolis, USA
3Department of Psychiatry, University of Minnesota Medical School, Minneapolis, USA
4Department of Neurology, University of Minnesota Medical School, Minneapolis, USA

ABSTRACT

Dementia is a leading cause of death worldwide, representing a significant global burden. In addition to genetic and lifestyle factors that have been widely linked to dementia, pathogens are increasingly recognized as contributing to the development of dementia. Here we discuss the role of human leukocyte antigens (HLA) in maintaining brain health by facilitating the elimination of pathogens and highlight evidence suggesting that the inability to eliminate pathogens contributes to dementia. Finally, we briefly review common forms of dementia including Alzheimer’s disease, vascular dementia, frontotemporal dementia, Lewy body dementia, and prion dementia in an effort to contextualize the role of persistent pathogens across the various dementia phenotypes.

Introduction

An estimated 50 million people are living with dementia worldwide, and that number is expected to triple by 20501. Dementia is a broad term that refers to conditions reflecting a decline in cognitive, behavioral, motor, and/or social functioning that eventually interferes with the ability to live independently. The most commonly recognized forms of dementia include Alzheimer’s disease (AD), vascular dementia, Lewy body dementias, and frontotemporal dementia. Prions and prion-like mechanisms associated with other neurodegenerative disorders are also implicated in dementia. The causal factors and mechanisms underlying brain deterioration associated with dementia as well as less pernicious forms of age-related cognitive decline have long been intensely investigated; however, there is a burgeoning emphasis on also understanding factors that promote the maintenance of healthy brain functioning across the lifespan. Here we will briefly review the emerging picture of immunogenetic mechanisms underlying brain health and disease centering around human leukocyte antigens (HLA) and discuss the implications of this immunogenetic influence in terms of common forms of dementia.

Healthy Brain Aging

It is widely accepted that the trajectory of cognitive functioning across the lifespan is influenced by both lifestyle factors such as diet and exercise as well as genetics. Among genetic influences, apolipoprotein E is well-established in playing a role in the maintenance of cognitive function and decline, depending on genotype. Specifically, the apolipoprotein E4 allele has been shown to be associated with brain atrophy2, neural network dysfunction3,4, increased risk for AD5,6, and reduced cognitive performance among cognitively healthy individuals7.
Conversely, the apoE2 alleles have been linked to preserved cognitive functioning and reduced risk of AD.

**HLA neuroprotection**

Emerging evidence suggests that HLA may also play a crucial role in brain health and disease. HLA genes encode for cell surface glycoproteins that are involved in immune surveillance and elimination of foreign antigens such as viruses and bacteria via the facilitation of cell destruction (Class I) or antibody production (Class II). These processes, however, hinge on a match between HLA molecules and antigenic peptides as a crucial step (Figure 1). The HLA genes are the most highly polymorphic in the human genome, an evolutionary consequence aimed at maximizing host protection from foreign antigens/pathogens. However, each individual has a limited repertoire of HLA molecules, restricting the scope of foreign antigens that can be successfully eliminated. Furthermore, HLA molecules differ in their binding affinity and ability to mount an immune response. Among the tens of thousands of HLA alleles, some occur at much higher frequencies in a population than others owing to their relative advantage in host protection via antigen elimination. For example, HLA DRB1*13 alleles have been shown to exert broad protective effects against several conditions affecting the brain, including various autoimmune disorders and Gulf War Illness, a neuroimmune condition related to military service during the 1990-91 Persian Gulf conflict.

With regard to Gulf War Illness, we found that HLA DRB1*13:02 protected against brain atrophy which is typical of those with the condition.

Brain atrophy is also viewed as a consequence of aging, with typical rates of atrophy approaching 5% per decade. Given the neuroprotective effects observed in other conditions, we investigated potential protective effects of HLA DRB1*13 against age-related brain changes. Again we found that HLA DRB1*13 alleles (HLA-DRB1*13:02 primarily but also HLA-DRB1*13:01 to a lesser extent) protect against age-related brain atrophy and function, even in the presence of apoE4. The role of HLA in pathogen elimination, in conjunction with evidence of HLA-DRB1*13 protection against age-related brain changes, led us to speculate that these alleles may protect against dementia via the elimination of pathogens. Indeed, in a recent genetic epidemiological study, we demonstrated that dementia prevalence (any type of dementia) in 14 Continental Western European countries is inversely associated with the population frequency of HLA DRB1*13:02 and was not accounted for by apoE4 (Figure 2a). In fact, as the population frequency of HLA DRB1*13:02 doubled, the prevalence of dementia was reduced by one-third (Figure 2b). Remarkably, the frequency of HLA DRB1*13:02 was shown to account for 45.2% of the variance in dementia rates. Given the role of HLA Class II alleles in elimination of foreign antigens by the production of specific antibodies against them, these findings suggest that individuals who possess the DRB1*13:02 allele, as well as populations in which the allele is common, have enhanced protection against dementia conferred by the successful elimination of the foreign pathogens. In the absence of such successful elimination, the pathogens may persist and cause inflammation and cell damage, leading to causally involved in dementia development. Unlike theories that are restricted to reactivation of latent infection as causing dementia, we proposed that the persistence of foreign pathogens, even in the absence of frank infection, may cause gradual damage to the brain that results in dementia.

**Pathogens and Dementia**

Once considered controversial, the role of pathogens in dementia is increasingly recognized and investigated. Indeed, numerous pathogens have been implicated in AD, including, most prominently, herpes viruses in addition to bacterial spirochetes such as those related to gum disease, among others. These infections have not only been shown to increase the risk of AD but the role of microbes...
in AD is also supported by evidence of the presence of microbes in brain tissue, particularly in regions that are impacted in AD, and co-localization of those microbes with typical AD pathology. A recent study of mice intranasally infected with the H5N1 virus provides a link between pathogens and Lewy body dementias (LBD). Specifically, the authors demonstrated that the H5NI virus enters the CNS via cranial nerves, affecting the brainstem first before spreading to the midbrain and cortex and that the virus can infect neurons by peripheral infection and by hematogenous spread subsequent to release from dying cells. Furthermore, they demonstrated aggregation of alpha-synuclein that co-localized with brain regions showing evidence of viral infection, including the hippocampus, cortex, and brainstem, similar to that seen in human proteinopathies. Finally, the authors reported evidence of microgliosis for the entire 90-day study period in spite of evidence that the acute infection had resolved by day 21, suggesting a prolonged inflammatory response resulting from the initial infection as might be expected with persistent pathogens. Prolonged inflammation has been linked to nearly all types of dementia. Furthermore, because brain regions that are critical to cognitive processes including memory, attention, emotion, and perception contain more enzymes involved in inflammatory responses than do other regions of the brain they are thought to be at increased risk of cumulative damage from even low-level chronic inflammation. The specific dementia phenotype may be dependent on the type of pathogen and its mode of entry into the brain. For example, microbial pathogens may cross the blood-brain-barrier and/or blood-cerebrospinal fluid barrier via one or more of several mechanisms, including transcellular penetration, paracellular entry, or by infected leukocytes circulating peripherally; they may also access the central nervous system through cranial nerves including most prominently the olfactory and trigeminal nerves before migrating to higher brain regions including those that have been implicated in dementia. Access to the CNS through the olfactory and trigeminal nerves has been shown to be highly relevant to human herpesviruses as well as several types of influenza A. Furthermore, researchers have demonstrated evidence of apoptosis in olfactory sensory neurons of virally-infected hosts which were suggested to be aimed at host protection from microbial invasion through the nasal cavity. Indeed, olfactory dysfunction resulting in loss of smell has been implicated in nearly every type of dementia. Taken together, compelling evidence supports the role of pathogens in dementia. Consistent with the mounting literature implicating pathogens in dementia and the immunogenetic (i.e., HLA) influence on pathogen elimination or, conversely, the persistence as described above, we have proposed the concept of persistent pathogen dementia which we characterize below.

**Persistent Pathogen Dementia (PPD)**

As noted above, several pathogens have been linked to dementia (primarily AD) including herpes simplex virus type 1 (HSV-1), *Helicobacter pylori* (h. pylori), *Chlamydia pneumonia*, and *Borrelia burgdorferi* among several others. Perhaps more than any other microbe, HSV-1 has been robustly associated with AD. The prevailing theory suggests that reactivation of latent HSV-1 infection in apoE4 carriers contributes to AD. The percent of dementia cases attributable to pathogens is unknown; however, evidence of HSV1 in the brains of apoE4 carriers has been shown in nearly 60% of cases, suggesting high rates of pathogen-linked dementia. In addition to current theories implicating reactivation of latent infections, we hypothesize that fragments of pathogens that elude...
elimination due to HLA-antigen incongruence will similarly affect the brain. To that end, any pathogen that is not able to be eliminated may contribute to PPD.

**Risk Factors**

The primary risk factor associated with PPD is exposure to pathogens (e.g., viruses, bacteria); however, rates of pathogen exposure do not square with rates of dementia indicating that pathogen exposure alone is not sufficient to produce dementia. For example, the majority of U.S. adults age 30 and older have been exposed to HSV-1 yet the U.S. population prevalence of dementia is less than 2% highlighting the role of additional factors. As with other dementias, apoE4 is considered a risk factor for PPDs. In the case of HSV-1, it has been suggested that HSV in apoE4 carriers is associated with high rates of dementia whereas neither apoE4 nor HSV1 alone raise risk. An additional risk-factor appears to be a lack of immunogenetic (i.e., HLA) protection. Because each HLA molecule matches specific epitopes, each person’s ability to eliminate pathogens is determined by their HLA profile as discussed above. Further, because each individual has a limited number of HLA genes that, in turn, determine which pathogens can be successfully eliminated, some individuals may lack protection against certain pathogens due to HLA-antigen incongruence.

**Neuropathology**

There is some evidence that neuropathology associated with persistent pathogens parallels and is associated with well-established dementia pathology. For example, HSN1 influenza has been shown to increase alpha-synuclein in pre-clinical studies. Similarly, HSV-1 has been shown to increase AD-related amyloid-beta (Aβ) and tau in cell cultures and to co-localize with amyloid plaques in the human brain. Typically, HIV has been shown to modulate the production of Aβ and tau. These findings dovetail with other lines of research demonstrating antimicrobial effects of Aβ and tau. That is, Aβ is thought to play a crucial role in the brain’s immune system by trapping pathogens. Similarly, there is evidence that tau accumulation is a neuroprotective response to oxidative stress, leading to the conclusion that “inclusion formation represents adaptation, or productive, beneficial response to otherwise neurodegenerative processes.” Thus, from the PPD perspective, in the absence of an HLA-antigen match, persistent foreign antigens promote the production of plaques and tangles in an effort to protect the brain from foreign invaders. Notably, such protective effects do not preclude the possibility that accumulation of Aβ and tau tangles eventually becomes toxic; however, this suggests that exposure to pathogens, in the absence of protective HLA that can eliminate them, plays a fundamental role in dementia.

**Neuroimaging**

Neuroimaging findings related to PPD are likely to be as varied as the underlying pathogens. Indeed, each of the herpes viruses has been associated with unique neuroimaging features, with reactivation following the same patterns as initial infection. Similarly, dementia related to HIV has been shown to be distinct from typical AD. Characteristic neuroimaging markers for various persistent pathogens may be identified in future studies.

**Treatment**

Effective interventions for PPD are likely to center around the elimination of pathogens. To that end, recent studies of anti-herpes antivirals have shown promise in reducing the incidence of dementia among individuals with herpes zoster and HSV1 in two large-scale studies. If research continues to support the hypotheses that Aβ and tau accumulation provide neuroprotective functions, and antimicrobial functions, in particular, treatments aimed at modulating Aβ and tau may not be effective; instead, if amyloid and tau are stimulated in order to protect the brain from pathogens, elimination of the pathogen is called for.

**Summary**

Thus far we have shown that immunogenetic protection conferred by HLA genes guards against neurodegeneration associated with neuroimmune conditions and age-related processes at the individual level, and protects against dementia at the population level via facilitating the elimination of pathogens. For those lacking immunogenetic protection, exposure to HLA-incongruent pathogens may persist, causing inflammation and neurodegeneration that may result in dementia. We have also shown that pathogens are increasingly recognized as playing a prominent role in dementia and provided an overview of characteristics proposed to be associated with PPD. Next, we provide a brief overview of commonly recognized types of dementia, noting evidence suggesting the role of pathogens in where applicable. We hypothesize that all dementias below, except for vascular dementia, are indeed subsets of PPD.

**Alzheimer’s Dementia**

AD is the most common cause of dementia, accounting for 60-80% of dementia cases. Although AD may be diagnosed before age 65, the vast majority of cases are seen in those 65 and above; the more typical late-onset type is the focus here. Memory impairments are the hallmark symptom of AD; however, impairments in judgment and social functioning, changes in mood and personality, and motor deficits are also typical. Because AD is a progressive disease, the level of dysfunction increases over time such that at the final stages, affected individuals are completely impaired and unable to perform basic life functions.
AD Risk factors

A number of risk factors have been associated with dementia. Among the non-modifiable risk factors are age and genetics. After age 65, the risk for dementia increases with age such that one-third of people aged 85 or older are diagnosed with dementia. A number of genes have been implicated in AD. Among genetic risk factors, the apolipoprotein E4 (apoE4) allele has the most robust association with AD risk increasing in a dose-dependent manner according to the number of apoE4 alleles. ApoE is involved in a number of functions including cholesterol transport and metabolism, neuroplasticity, and neuronal repair. Relative to apoE2 and E3, the E4 allele is unstable and its expression results in neurotoxic fragments that ultimately contribute to neurodegeneration. However, apoE4 is neither necessary nor sufficient to produce AD; recent studies have identified various other genes that appear to be related to AD including several associated with immune response and inflammation. In addition to non-modifiable risk factors, a number of lifestyle-related factors have been implicated in dementia including diet, physical and mental exercise, diabetes, obesity, and smoking. Evidence suggests that a reduction in modifiable risk factors would lead to a significant decline in dementia incidence. The recent decline in dementia incidence in many countries may be attributable to reduced risk owing to changes in modifiable risk factors. Finally, as previously noted, numerous pathogens have been implicated as a risk factor for AD.

AD Neuropathology

The hallmark signs of AD are extracellular Aβ plaques and intracellular neurofibrillary tau tangles. Amyloids are protein aggregates that stick together forming fibrils. In the case of AD, it is believed that misfolded Aβ oligomers accumulate, forming plaques that disrupt synapses and ultimately contribute to neurodegeneration. Protein misfolding and aggregation has also been implicated in Parkinson’s disease and prion diseases, both of which are also associated with dementia. Indeed, it has been suggested that Aβ and tau are themselves prion-like in that they may slowly self-propagate, ultimately contributing to widespread neurodegeneration. Despite considerable evidence linking Aβ to dementia, mounting research has called into question the central role of Aβ plaques in AD. First, postmortem autopsy of brain specimens and in vivo positron emission tomography have revealed evidence of significant amyloid plaque burden in the absence of memory impairment. Second, as summarized elsewhere, several therapeutic strategies aimed at clearing Aβ from the brain have failed, and in some cases, produced severe side effects. Finally, Aβ has been shown to have important physiological functions including anti-microbial activity. That is, accumulation of Aβ may result from immune-mediated mechanisms aimed at trapping pathogens, the persistence of which could facilitate the accumulation of Aβ. While it is recognized that Aβ likely participates in dementia, there are growing calls for the scientific community to “devote its utmost efforts to identify the real culprit of AD,” which we have proposed is persistent pathogens.

Tau is a highly soluble protein involved in microtubule stabilization, primarily in axons, that has also been implicated in AD. In the AD brain, tau is hyperphosphorylated relative to healthy tau. Hyperphosphorylated tau becomes insoluble and misfolded protein aggregates form neurofibrillary tangles that accumulate in cells leading to impairment in several downstream processes including mitochondrial and synaptic function and axonal transport, and ultimately cell death. Tau has also been implicated in AD-associated neuroinflammation and has been shown to interact with insulin to modulate AD. Tau tangles are more correlated with cognitive impairment and AD severity than Aβ, leading many to consider tau as fundamentally underlying AD. However, others have noted evidence of tau pathology in prepubertal human brains and in cognitively healthy individuals, and have shown that neurons with neurofibrillary tangles can live for decades, raising criticism for the hypothesis that tau mutations drive AD. Furthermore, as with Aβ, some have suggested that phosphorylated tau (and other intracellular inclusions) serve a neuroprotective role against adverse conditions such as oxidative stress and/or toxin exposure. In this scenario, in which hyperphosphorylation of tau is secondary to other local cellular environmental insults, the long-term consequences may be deleterious (including neuronal death) albeit protracted. Finally, if tau indeed serves a protective role, AD interventions aimed at reducing tau pathology may be counterproductive.

AD Neuroimaging

Considerable effort is being made to detect AD in vivo with diagnostic neuroimaging moving along several fronts. Structural MRI is one of the most widely used neuroimaging techniques in the diagnosis of AD. Decades of research have converged to establish a signature of AD-related brain atrophy characterized by initial effects on the medial temporal lobe (i.e., entorhinal cortex and hippocampus), followed by an extension to the rest of the cortex, with the motor areas spared until later in the disease process, as reviewed elsewhere. In addition, several subcortical structures including the amygdala, basal ganglia, caudate, and putamen, among others have been shown to exhibit significant atrophy in patients with AD. Advances in neuroimaging have helped identify several subtypes of AD that are atypical relative to the AD signature described above. Indeed, mounting evidence suggests there is substantial heterogeneity in patterns of brain atrophy.
associated with AD with several subtypes following atypical patterns including one that spares the hippocampus, one that predominantly involves limbic structures, and one that is characterized by minimal atrophy. Although speculative, it is possible that the heterogeneity observed in AD is related to the varied mechanisms of pathogen entry into the brain as described previously.

Positron emission tomography (PET) is also widely utilized in clinical evaluations of AD. Amyloid, tau, and \(^{18}\)fluorodeoxyglucose (FDG) PET tracers have been used to noninvasively visualize amyloid and tau deposition and glucose consumption in the brain, respectively, each providing novel and complementary indications of AD-related pathological processes. PET is also being used for in vivo detection of neuroinflammation as evidenced by microglia activation and reactive astrogliosis. Increasingly, clinical scientists are advocating for the use of multimodal neuroimaging to detect the variety of pathological brain changes associated with AD, and ultimately increase diagnostic accuracy.

**AD Treatment**

To date, there is no cure for AD and treatment is aimed at managing symptoms as reviewed elsewhere. Briefly, cholinesterase inhibitors and Memantine, an NMDA receptor agonist, have been licensed for AD with some benefit observed for cognition and mood symptoms. Neuropsychiatric symptoms in AD are commonly treated with atypical antipsychotics, antidepressants, or anticonvulsants with modest benefits and, in some cases, the potential for significant side effects. Finally, several disease-modifying treatments are under investigation, many of which are aimed at targeting amyloid-beta and tau; none have shown conclusive efficacy for AD yet. Given the lack of effective treatments for AD, the importance of AD prevention through lifestyle interventions such as exercise and a healthy diet has gained prominence.

**Lewy Body Dementia and Parkinsonian Dementia**

Lewy Body dementia (LBD), which include dementia with Lewy bodies and Parkinson's disease dementia, are the second most common type of dementia in older adults, accounting for up to 30% of dementia cases. Men are disproportionately affected by LBD. Clinically, LBDs are difficult to distinguish from AD in that both are characterized by a progressive decline in cognitive function, however, LBD is characterized by periods of normal cognition alternating with a cognitive impairment which is not typical of AD. Individuals with LBD are also prone to hallucinations and parkinsonian motor symptoms, and rapid eye movement sleep behavior disorders are common and have been shown to be predictive of LBD.

**LBD Neuropathology**

As with several other forms of dementia, misfolded aggregated proteins are associated with LBD. The hallmark of LBD is alpha-synuclein neuronal inclusions. Alpha-synuclein is a protein found predominantly in the brain (e.g., neocortex, hippocampus, substantia nigra, thalamus, and cerebellum) but also in other organs such as the heart and lungs. In the brain, it is widely found in the presynaptic terminals in addition to the cytosol. Under normal conditions, alpha-synuclein is thought to be involved in neurotransmitter release and has been shown to have several neuroprotective functions including suppression of apoptosis, regulation of glucose and dopamine, and antioxidant functions among others. However, under pathologic conditions, alpha-synuclein misfolds forming fibrils that deposit as Lewy bodies. It is unclear why alpha-synuclein aggregates; as with other forms of dementia, oxidative stress and mutations are thought to play a role. Lewy pathology is accompanied by the substantial neuronal loss that has been documented in the substantia nigra, locus coeruleus and basal nucleus of Meynert, among other regions.

In addition to alpha-synuclein, Aβ plaques and tau tangles are often present in LBD. Similar to the discussion above regarding Aβ and tau, questions about whether alpha-synuclein is neuroprotective or neurotoxic have arisen. In support of a neuroprotective role, Lewy bodies have been shown to isolate harmful proteins (which could include persistent pathogens) similar to the antimicrobial role of Aβ, (which could include persistent pathogens) similar to the antimicrobial role of Aβ. In addition, inclusion body formation does not necessarily lead to cell death. Further, there is evidence of severe alpha-synuclein pathology in the absence of clinical symptoms, highlighting a disconnect between alpha-synuclein pathology and dementia.

**LBD Risk Factors**

A number of genetic risk factors have been associated with LBD including mutations in SNCA, the gene that encodes the alpha-synuclein protein, as well as genes implicated in other forms of dementia such as those associated with amyloid precursor protein, presenilin genes, tau, and apoE.

**LBD Imaging**

Like AD, LBD is associated with global atrophy, rendering structural imaging less helpful in differentiating LBD from AD. Other neuroimaging techniques, however, have proven more useful in terms of differential diagnosis of LBD from AD. Briefly, LBD, in particular, has been associated with occipital hypometabolism, less hippocampal atrophy, and significantly reduced dopamine reuptake in the caudate and putamen relative to AD.
LBD Treatment

Like AD, treatment of LBD is aimed at symptom management, and acetylcholinesterase inhibitors are commonly prescribed to slow the progression of cognitive deficits. As noted in a recent review, treatments targeting other symptoms have insufficient evidence regarding efficacy and, in many cases, evidence of adverse effects limit the benefit of several medications aimed at symptom management. As with other proteinopathies, treatments aimed at decreasing the accumulation of alpha-synuclein are being investigated as the future of LBD treatment.

Vascular Dementia

Vascular dementia (VaD), sometimes referred to as vascular cognitive impairment, accounts for about 15% of dementia cases. VaD results from reduced blood flow to the brain resulting in cortical and/or subcortical damage. Although the symptoms of VaD are variable depending on which area of the brain is affected by vascular pathology, deficits in planning and judgment are commonly observed (for an overview of VaD, see ). Depression is also particularly common in VaD. Unlike AD, where memory impairment is a hallmark, the memory may or may not be impaired in VaD. The symptom course is also variable. Some experience sudden onset of symptoms, particularly following a stroke, some exhibit a stepwise progression of symptoms and others a slow steady progression similar to that seen in AD. Finally, VaD and AD often co-occur with up to 50% of individuals showing evidence of “mixed dementia”, making it among the most common in older adults.

VaD Risk Factors

Several vascular dementia risk factors mirror those associated with heart disease including hypertension, high cholesterol, diabetes, smoking, sedentary lifestyle, unhealthy diet, being overweight, limited exercise, and high alcohol consumption. Notably, these factors have been associated with inflammation which has been shown to contribute to atherosclerosis and subsequent risk of stroke and cognitive impairment. Stroke history is a significant risk factor for vascular dementia with nearly 25% of people who have had a stroke ultimately developing dementia. As with other forms of dementia, increasing age is a risk factor for vascular dementia. Identification of genetic risk factors for VaD has been limited; however, like AD, apoE4 has been associated with VaD.

VaD Neuroimaging and Neuropathology

The presence of infarcts, lacunes, and white matter lesions as evidenced by neuroimaging are indicative of VaD. However, due to the heterogeneity of cerebrovascular pathology and evidence of vascular brain pathology in non-demented older individuals, there are no accepted neuropathological criteria specific for VaD.

VaD Treatment

To date, pharmacological interventions for VaD have shown limited effectiveness. Interventions for AD, such as cholinesterase inhibitors and memantine, are not recommended due to side effects and small magnitude benefits observed in VaD relative to AD. Other pharmacological interventions aimed at reducing risk factors such as high cholesterol or hypertension have typically not included cognitive status as a primary outcome, rendering conclusions about effectiveness in reducing dementia risk untenable. Preventive lifestyle interventions such as healthy eating and increased exercise have shown promising results in terms of improving or maintaining cognitive functioning in at-risk elderly people. The effectiveness of lifestyle interventions is at least partially attributable to reductions in peripheral inflammation.

Frontotemporal Dementia

Frontotemporal dementia (FTD) is the third most common cause of dementia, with prevalence ranging from 3-26% of dementia cases, and is particularly common in early-onset dementia. Three variants of FTD have been identified based on early symptoms and are reviewed elsewhere. First, behavioral-variant FTD is characterized by personality changes, disinhibition, and apathy, often resembling psychiatric disorders. Unlike AD where memory impairment is prominent, memory and visuospatial skills are often spared in the early stages of behavioral-variant FTD. There may be a slow progression of cognitive impairment and neuroimaging is often unremarkable. Primary progressive aphasias are characterized primarily by a decline in language skills during the initial phase of the disease. In semantic-variant primary progressive aphasia, symptoms to include anoma, word-finding difficulties, and impaired comprehension. Non-fluent variant primary progressive aphasia is characterized by grammatical errors and speech apraxia. As any of the variants of FTD progress, the symptoms converge and cognitive and motor deficits emerge, ultimately resembling AD.

FTD Risk Factors

A family history of dementia is associated with FTD. To that end, a number of genetic mutations including, but not limited to, mutations associated with tau, TAR DNA-binding protein-43 (TDP-43), fused-in sarcoma (FUS), and ubiquitin have been associated with FTD. A succinct review of several genetic mutations associated with FTD, brain pathology that is characteristic of each mutation, and mechanisms of degeneration is available in a recent FTD overview. Notably, several studies have noted strong associations between HLA Class II DR and FTD including...
evidence of cis-changes in methylation levels of HLA-DR in the frontal cortex and a significant reduction in HLA-DR expression if FTD relative to controls.

FTD Neuropathology

Similar to AD, abnormal protein deposition has been implicated in FTD. Tau, TAR DNA-binding protein-43 (TDP-43), or FUS protein account for most cases of FTD and are associated with characteristic neuropathological signs (e.g., Pick bodies, tufted astrocytes, as described elsewhere.

FTD Imaging

Neuromaging studies have demonstrated similarities across FTD variants as well as unique features. Atrophy in ventromedial and posterior orbital frontal regions, insula, and anterior cingulate cortex have been demonstrated across FTD variants; however, the behavioral variant is predominantly associated with dorsolateral frontal atrophy whereas the semantic variant is primarily associated with bilateral anterior temporal atrophy. The selective frontal and temporal lobe neurodegeneration in FTD has been attributed to the degeneration of von Economo neurons and fork cells which are thought to integrate cortical and subcortical networks; degeneration of von Economo neurons and fork cells are not found in AD or healthy brains. In addition, as summarized elsewhere, amyloid tracer imaging, diffusion tensor imaging, and functional connectivity studies have proven useful in distinguishing FTD from AD.

FTD treatment

Treatment for FTD is often aimed at reducing behavioral symptoms with common psychiatric medications, particularly selective serotonin reuptake inhibitors, widely prescribed. Novel treatments aimed at inhibiting aggregation of tau and other proteins are under investigation.

Mixed Dementia

Further complicating research aimed at distinguishing types of dementia is the fact that dementias often co-occur. VaD and AD, in particular, have been shown to co-occur with high rates of overlapping brain pathology (i.e., both evidence of vascular damage along with amyloid plaques and neurofibrillary tangles), sometimes in addition to evidence of Lewy bodies. The high rates of overlap point to a combination of different neurodegenerative processes that underlie cognitive deterioration associated with dementia.

Prion Dementia

Prion diseases such as Creutzfeldt-Jakob disease (CJD) represent a rare type of dementia caused by misfolded, self-propagating, rapidly accumulating prion proteins, the result of which is neurodegeneration. In contrast to most other dementias that progress slowly, prion dementias are often characterized by rapid progression with death occurring within a few months to years of onset. Prion diseases are most often spontaneous (80-95%) but can also be genetic (familial; 10-15%) or, on rare occasions, acquired through accidental transmission (e.g., surgical or ingestion of infected meat; 1%) Typical symptoms of spontaneous CJD, the most common prion disease, include imbalance and incoordination, memory loss and impaired thinking, and psychiatric symptoms such as anxiety or depression; however, CJD affects many areas of the brain and its presentation is variable and often initially difficult to distinguish from neurologic or psychiatric conditions.

Prion Dementia Risk Factors

Mutations in the human prion protein gene, PRNP, that make the protein more susceptible to misfolding, appear to be associated with various forms of prion diseases.

Prion Dementia Neuropathology

Neuropathological findings of prion diseases include varying severity of atrophy, vacuolation, astrocytic gliosis, and prion protein amyloid plaque deposition. Prion-related neuropathological findings are reviewed elsewhere. Notably, prions tend to co-localize with amyloid plaques and have been shown to promote plaque formation.

Prion Dementia Imaging

Brain MRI has been shown to have high diagnostic utility for sporadic CJD. Specifically, restricted diffusion in cortical or deep nuclei gray matter and hyperintensity in cortical gyri, caudate, putamen, or thalamus have been associated with both sporadic and familial forms of CJD; however, gross abnormalities may also be absent. Acquired CJD can be distinguished from other human prion diseases by the "pulvinar sign," in which the pulvinar is brighter than the anterior putamen.

Prion Dementia Treatment

There are no treatments for prion diseases and the often rapid progression of the disease renders clinical trials a significant challenge. Similar to other neurodegenerative disorders, however, pharmacological interventions are currently being investigated along several fronts including immunotherapy and prevention of prion protein aggregation with doxycycline, thus far with mixed or negative results. Promising initial studies aimed at preventing prion protein conformational changes have shown evidence of decreased vacuolation and prion protein deposition along with slowed neurological and psychiatric symptom progression in mice and macaques. Effective treatments in humans remain to be discovered.
Conclusions

Growing evidence suggests pathogens may play a crucial role in the development of dementia. Compelling evidence over the last several decades has strongly implicated pathogens in AD and emerging evidence suggests that pathogens may be involved in other dementias as well. We have hypothesized that exposure to pathogens in the absence of immunogenetic protection against those pathogens (due to HLA-antigen) incongruence leads to dementia. Conversely, an HLA-antigen match with sufficient binding affinity and ability to mount an immune response may protect against dementia. This perspective focuses on the evolutionary protective role of HLA in the elimination of foreign pathogens to facilitate host protection against a variety of conditions including dementia.

Acknowledgments

Support was provided by the University of Minnesota (the Kunin Professorship for Women’s Healthy Brain Aging, the Brain and Genomics Fund, the McKnight Presidential Chair of Cognitive Neuroscience, and the American Legion Brain Sciences Chair) and the U.S. Department of Veterans Affairs. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government.

References

1. World Health Organization. (2017). Dementia: Fact sheet. Retrieved from http://www.who.int/mediacentre/factsheets/fs362/en/
2. Chen K, Reiman EM, Alexander GE, et al. Resting-state network disruption and APOE genotype in Alzheimer’s disease: a lagged functional connectivity study. PLoS One. 2012; 7(9): e46289.
3. Leuthold AC, Mahan MY, Stanwyck JJ, et al. The number of cysteine residues per mole in apolipoprotein E affects systematically synchronous neural interactions in women's healthy brains. Exp Brain Res. 2013; 226: 525-536.
4. Corder EJ, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993; 261: 921-923.
5. Leutolf HD, Mahan MY, Stanwyck JJ, et al. The number of cysteine residues per mole in apolipoprotein E affects systematically synchronous neural interactions in women’s healthy brains. Exp Brain Res. 2013; 226: 525-536.
6. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013; 45: 1452-1458.
7. Wisdom NM, Callahan JL, Hawkins KA. The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol Aging. 2011; 32: 63-74.
8. Liu CC, Kanekyo T, Xu H, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013; 9: 106-118.
9. Bettencourt A, Carvalho C, Leal R, et al. The Protective Role of HLA-DRB1*13 in Autoimmune Diseases. J Immunol Res. 2015; e948723.
10. Furukawa H, Oka S, Tsuchya N, et al. The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases. Genes and Immunity. 2017; 18: 1-7.
31. Alves J, Petrosyan A, Magalhães R. Olfactory dysfunction in dementia. World Journal of Clinical Cases WJCC. 2014; 2(11): 661.

32. Itzhaki RF, Lin WR, Shang D, et al. Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. The Lancet. 1997; 349(9047): 241-4.

33. McQuillan G, Kruzon-Monn D, Flagg EW, et al. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14–49: United States, 2015–2016. NCHS Data Brief, no 304. Hyattsville, MD: National Center for Health Statistics. 2018.

34. Matthews KA, Xu W, Gaglioti AH, et al. Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged ≥65 years. Alzheimers Dement. 2019; 15: 17–24.

35. Wozniak MA, Frost AL, Itzhaki RF. Alzheimer’s disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J Alzheimers Dis. 2009; 16: 341–350.

36. Wozniak MA, Itzhaki RF, Slipher SJ, et al. Herpes simplex virus infection causes cellular β-amyloid accumulation and secretase upregulation. Neurosci Lett. 2007; 429: 95–100.

37. Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques. J Pathol. 2009; 217: 131–138.

38. Canet G, Dias C, Gabelle A, et al. HIV neuroinfection and Alzheimer’s disease: Similarities and potential links? Front Cell Neurosci. 2018; 12: 307.

39. Li H, Liu CC, Zheng H, et al. Amyloid, tau, pathogen infection and neurodegenerative disease: The role of amyloid-β and tau. J Alzheimers Dis. 2019; 54: 859–878.

40. Moir RD, Lathe R, Tanzi RE. The antimicrobial protection hypothesis of Alzheimer’s disease. Alzheimers Dement. 2018; 14(12): 1602–14.

41. CastelBani BJ, Lee HG, Perry G, et al. Antioxidant protection and neurodegenerative disease: The role of amyloid-β and tau. Am J Alzheimers Dis. 2006; 21(2): 126-130.

42. Soares BP, Provenzale JM. Imaging of herpesvirus infections of the CNS. AJR Am J Roentgenol. 2016; 206: 39–48.

43. Milanini B, Valcour V. Differentiating HIV-associated neurocognitive disorders from Alzheimer’s disease: an emerging issue in geriatric NeuroHIV. Current HIV/AIDS Reports. 2017; 14(4): 123-32.

44. Chen VCH, Wu SI, Huang KY, et al. Herpes zoster and dementia. J Clin Med. 2018; 7(12): 307-87.

45. Tzeng NS, Chung CH, Lin FH, et al. Antiherpetic medications and reduced risk of dementia in patients with herpes simplex virus infections—a nationwide, population-based cohort study in Taiwan. Neurotherapeutics. 2015; 18: 417–429.

46. Alzheimers Association. 2019 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2019; 15(3): 321-87.

47. Carmona S, Hardy J, Guerreiro R. The genetic landscape of Alzheimer disease. In Handbook of Clinical Neurology. 2018; Vol 148: 395-408. Elsevier 2018.

48. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention and care. The Lancet. 2017; 390(10113): 2673-734.

49. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegenerative disease: Similarities and potential links? Front Cell Neurosci. 2018; 12: 307.

50. Aoyagi A, Condello C, Stöhr J, et al. AB and tau prion-like activities decline with longevity in the Alzheimer’s disease human brain. Sci Transl Med. 2019; 11: eaat4862.

51. Brundin P,Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2010; 11(4): 301.

52. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013; 501: 45–51.

53. Ricciarelli R, Fedele E. The amyloid cascade hypothesis in Alzheimer’s Disease: It’s time to change our mind. Curr Neuropharmacol. 2017; 15(6): 926–935.

54. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999; 45(3): 358-68.

55. Wolf DS, Gearing M, Snowden DA, et al. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alz Disease Assoc Dis. 1999; 13(4): 226-31.

56. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008; 65: 1509-1517.

57. Bourgade K, Dupuis G, Frost EH, et al. Anti-viral properties of amyloid-β peptides. J Alzheimers Dis. 2016; 54: 859–878.

58. Kumar DK, Choi SH, Washicosky KJ, et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med. 2016; 8: 340ra72.

59. Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. PNAS. 1986; 83: 4913–4917.

60. LabzinLI, Heneka MT, Latz E. Innate immunity and neurodegeneration. Annu Rev Med. 2018; 69: 437–49.

61. Rodriguez-Rodriguez P, Sandebrøe-Bratton A, Merino-Serrais P, et al. Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons. Brain. 2017; 140: 3269–85.

62. Giannakopoulos P, Herrmann FR, Busi, R et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology. 2003; 60: 1495–500.

63. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239–59.

64. Braak H, Thal DR, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011; 70: 960-969.

65. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age-specific and sex-specific prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017; 16: 435–44.

66. Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol. 1999; 58: 188–97.

67. Lee HG, Perry G, Moreira PI, et al. Tau phosphorylation in Alzheimer’s disease: pathogen or protector?. Trends Mol Med. 2005; 11(4): 164–169.

68. Pini L, Plevani M, Bocchetta M, et al. Brain atrophy in Alzheimer’s disease and aging. Ageing Res Rev. 2016; 30: 25-48.

69. Poulakis K, Pereira JB, Mecocci P, et al. Heterogeneous patterns of brain atrophy in Alzheimer’s disease. Neurobiol Aging. 2018; 65: 98-108.

70. Murray IVJ, Lee VMY, Trojanowski JQ. Synucleinopathies: A pathological and molecular review. Curr Neurosci Res. 2001; 1: 445.

71. Femminella G, Thayanandan T, Calsolaro V, et al. Imaging and pathological and molecular review. Clin Neurosci Res. 2001; 1: 445.

72. Ballard C, Gauthier S, Corbett A, et al. Alzheimer’s disease: It’s time to change our mind. Curr Neuropharmacol. 2017; 15(4): 301.

73. Savica R, Grossardt BR, Bower JL, et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013; 70: 1396.
74. Walker Z, Possin KL, Boeve BF, et al. Lewy body dementia. The Lancet. 2015; 386(10004): 1683-97.

75. Emamzadeh FN. Alpha-synuclein structure, functions, and interactions. J Res Med Sci. 2016; 21: 29.

76. Benskey MJ, Perez RG, Manfredsson FP. The contribution of alpha-synuclein to neuronal survival and function—implications for Parkinson’s disease. J Neurochem. 2016; 137: 331–359.

77. Zarrow C, Lyness SA, Mortimer JA, et al. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003; 60: 337–41.

78. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: convergence of alpha-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci. 2013; 14(9): 626-36.

79. Tanaka M, Kim YM, Lee G, et al. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem. 2004; 279: 4625-4631.

80. Castellani RJ, Siedlak SL, Perry G, et al. Sequestration of iron by Lewy bodies in Parkinson’s disease. Acta neuropathologica. 2000; 100(2): 111-4.

81. Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/subtyping criteria for frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol. 2014; 13: 686–699.

82. Forloni G, Salmona M, Marcon G, et al. Tetracyclines and prion diseases. Acta Neuropathol. 2001; 101: 417–423.

83. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer’s disease and its subtypes: a genome-wide association study. Lancet Neurol. 2005; 344: 1516-1526.

84. Varga J, Ford E. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology. 2002; 13: 561–568.

85. Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies and its subtypes: a genome-wide association study. Lancet Neurol. 2015; 385(10004): 1672-82.

86. Corcoran ML, Georgopoulos AP. Dementias Caused by Persistent Pathogens and the Protective Role of HLA Against them. J Neurol Neuromed (2020) 5(1): 1-11

87. Ferrari R, Hernandez DG, Nalls MA, et al. Frontotemporal dementia and vascular dementia: association with education and its subtypes: a genome-wide association study. Lancet Neurol. 2014; 13: 686–699.

88. Prusiner SB. Prions. PNAS. 1998; 95(23): 13363–13383.

89. Kempermann G, Gage FH. Adult hippocampal neurogenesis. Annu Rev Neurosci. 2002; 25: 105-30.

90. Schneider JA. High blood pressure and microinfarcts: a link between vascular risk factors, dementia, and clinical Alzheimer’s disease. J Am Geriatr Soc. 2009; 57(11): 2146-7.

91. Prusiner SB. Prions. PNAS. 1998; 95(23): 13363–13383.

92. Prusiner SB. Neurodegenerative diseases and prions. N Engl J Med 2001; 344: 1516-1526.

93. Geschwind MD. Prion diseases. Continuum Minn. 2015; 21:1612–1638.

94. Voigtlander T, Kloppe S, Birner P, et al. Marked increase of neuronal prion protein immunoreactivity in Alzheimer’s disease and human prion diseases. Acta Neuropathol 2001; 101: 417–423.

95. Schwarze-Eicker K, Keyvan K, Görtz N, et al. Prion protein (PrPc) promotes beta-amyloid plaque formation. Neurobiol Aging. 2005; 26: 1177–1182.

96. Prusiner SB. Prions. PNAS. 1998; 95(23): 13363–13383.

97. Pohjasvaara T, Mäntylä R, Soininen H, et al. How complex interactions of ischemic brain infarcts, white matter lesions, and atrophy relate to poststroke dementia. Arch Neurol. 2000; 57(9): 1295-300.

98. Voigtlander T, Kloppe S, Birner P, et al. Marked increase of neuronal prion protein immunoreactivity in Alzheimer’s disease and human prion diseases. Acta Neuropathol 2001; 101: 417–423.

99. Ratliff TC, Gallo JJ, Feifel D, et al. Neuronal death and the immune system in dementia. J Alzheimers Dis. 2017; 58: 1303–1313.

100. Schneider JA. High blood pressure and microinfarcts: a link between vascular risk factors, dementia, and clinical Alzheimer’s disease. J Am Geriatr Soc. 2009; 57(11): 2146-7.